Comparison of the efficacy and safety of dulaglutide in combination with insulin compared with insulin alone in daibetes patients who are receiving high dose glucocorticoids therapy: a randomized,open-label trial

INTERVENTION: Combination therapy with dulaglutide and insulin group:Injection of 0.75mg dulaglutide once a week, before breakfast Multiple injection of rapid acting insulin and NPH insulin.Adjust the insulin dose according to the algorithm to keep blood glucose of before each meal 90‐130mg/dl,2 hours after meals less than 180mg/dl.Obsevation period:24 weeks after the administration. Insulin monotherapy group: Multiple injection of rapid acting insulin and NPH insulin.Adjust the insulin dose according to the algorithm to keep blood glucose of before each meal 90‐130mg/dl,2 hours after meals less than 180 mg/dl.Obsevation period:24 weeks after the administration. CONDITION: Diabetes mellitus PRIMARY OUTCOME: Change of HbA1c at the 24th week SECONDARY OUTCOME: Change of date shown below at the 12th and 24th week.; HbA1c(at the 12th week),GA,body weight,blood pressure,total cholesterol,triglyceride,LDL‐cholesterol,HDL‐cholesterol,fasting plasma glucose,c‐peptide(at the 24th week),urine albumin(mg/gCr)(at the 24th week),KL‐6 INCLUSION CRITERIA: 1Patients treated with insulin therapy 2Patients expected to have high‐dose steroid(10mg or more of prednisolone each day) during the next 6 months